SG Americas Securities LLC Acquires 18,815 Shares of Harrow, Inc. (NASDAQ:HROW)

SG Americas Securities LLC raised its holdings in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 158.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,689 shares of the company's stock after buying an additional 18,815 shares during the quarter. SG Americas Securities LLC owned about 0.09% of Harrow worth $1,030,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Quest Partners LLC purchased a new position in Harrow during the third quarter worth about $29,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock worth $57,000 after purchasing an additional 227 shares in the last quarter. Hills Bank & Trust Co purchased a new position in shares of Harrow in the 3rd quarter worth about $107,000. Huntington National Bank purchased a new position in shares of Harrow in the 3rd quarter worth about $164,000. Finally, Clarus Group Inc. purchased a new position in shares of Harrow in the 3rd quarter worth about $225,000. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Trading Down 3.1 %

Shares of NASDAQ HROW traded down $0.97 during midday trading on Friday, reaching $30.72. The company had a trading volume of 819,991 shares, compared to its average volume of 271,961. Harrow, Inc. has a one year low of $9.13 and a one year high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The firm's fifty day moving average price is $35.93 and its 200-day moving average price is $39.52. The stock has a market cap of $1.09 billion, a PE ratio of -32.68 and a beta of 0.72.

Analyst Ratings Changes

HROW has been the subject of a number of research reports. B. Riley cut their price objective on Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a report on Wednesday, December 4th. Lake Street Capital upped their price objective on Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a report on Friday, October 4th. Finally, Craig Hallum upped their price objective on Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a report on Friday, October 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.